Even though treatment methods such as the angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) are available (Inker et al., 2014) and, more recently, a sodium-glucose cotransporter 2 (SGLT2) (Cherney et al., 2020; Heerspink et al., 2020) for the treatment of diabetic and non-diabetic CKD patients, risk of CKD progression remains high (Perkovic et al., 2019), and new therapies are needed. This evidence concerns the gene SLC5A2 and chronic kidney disease.